The developed AI-based vehicle detection model and tool have shown enhanced accuracy in traffic management, outperforming ...

Trapped immune cells laden with microplastics starve the brain of oxygen—mouse study links vascular blockages to memory loss and motor deficits, with lingering risks even after symptoms fade.

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

FastGlioma vs image- and fluorescence-guided adjuncts better detected tumor infiltration during surgery by a large margin.

The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients ...

Let’s cut to the chase: erectile dysfunction (ED) is a common issue, but it’s not the end of the world. Not even on Valentine ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

The sheer size of the place is enough to make your head spin faster than a disco ball at a 70s-themed party. Racks upon racks ...

A team of researchers from the National University of Singapore (NUS) has developed a novel method to enhance the precision of cancer treatment using gold nanoparticles tagged with DNA ...